MedTrace Logo

The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy

NCT01880372 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2019-02-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the role of alpha lipoic acid in patients who have moderate non-proliferative diabetic retinopathy.

The primary aim of this study is to test the hypothesis that the addition of alpha lipoic acid in a diabetic patient's therapeutic regimen can decrease the progression of diabetic retinopathy and preserve visual acuity.

Conditions

  • Moderate Non-proliferative Diabetic Retinopathy

Interventions

DIETARY_SUPPLEMENT

Alpha Lipoic Acid

Same as Arm description

Sponsors & Collaborators

  • Retina Specialists of Michigan

    collaborator UNKNOWN

  • Ferris State University

    lead OTHER

Principal Investigators

  • Arinze Nkemdirim Okere, PharmD, MS · Florida A & M University, College of Pharmacy and Pharmaceutical sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01880372 on ClinicalTrials.gov